Savolitinib as a novel treatment regimen for pulmonary sarcomatoid carcinoma with MET exon 14 skipping mutation.
Wang Y, Bu Y, Che G.
Asian J Surg · letter; case reports · DOI 10.1016/j.asjsur.2024.03.165 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för savolitinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
38 träffarMorphological Control of Crystalline Savolitinib via the Volatile Deep Eutectic Solvent Technique.
Symons JE, Hall C, McCabe JF, Hall SR.
Cryst Growth Des · research-article; journal article · DOI 10.1021/acs.cgd.4c00035Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
Chen L, Chen JF, He JT, Rong H, Zhuang X, Peng J.
Anticancer Drugs · review; journal article; case reports · DOI 10.1097/cad.0000000000001581Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation.
Ren X, Li K, Zhang Y, Zou C, Su M.
Front Oncol · journal article; case reports; case-report · DOI 10.3389/fonc.2024.1297156Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
Roper N, El Meskini R, Maity T, Atkinson D, Day A, Pate N, Cultraro CM, Pack S, Zgonc V, Weaver Ohler Z, Guha U.
Cancer Res Commun · research-article; journal article · DOI 10.1158/2767-9764.crc-23-0321Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion.
Ouyang G, Shu P, Xue Y, Luo F, Li Y.
Onco Targets Ther · journal article; case reports; case-report · DOI 10.2147/ott.s442685Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation.
Liu Z, Li P, Wu Q, Zhou Q.
Asian J Surg · letter; case reports · DOI 10.1016/j.asjsur.2023.12.167Interstitial pneumonia disease induced by osimertinib combined with savolitinib targeted therapy in a lung cancer patient: A case report.
Shen Y, Lou S, Zhang J.
Medicine (Baltimore) · research-article; journal article; case reports · DOI 10.1097/md.0000000000036208Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib.
Zhang L, Wang Y, Lin L, Yu Y, Lu S.
Ther Adv Med Oncol · research-article; journal article · DOI 10.1177/17588359231216089Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review.
Zhou K, Liu Y, Zhu H.
Front Oncol · journal article; case reports; case-report · DOI 10.3389/fonc.2023.1254026Savolitinib: A Promising Targeting Agent for Cancer.
Lee TS, Kim JY, Lee MH, Cho IR, Paik WH, Ryu JK, Kim YT, Lee SH.
Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers15194708Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report.
Yan N, Zhang Z, Guo S, Shen S, Li X.
Front Med (Lausanne) · published erratum; correction · DOI 10.3389/fmed.2023.1256685Erratum: Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Författaruppgift saknas
J Clin Oncol · published erratum · DOI 10.1200/jco.23.01150Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report.
Yan N, Zhang Z, Guo S, Shen S, Li X.
Front Med (Lausanne) · journal article; case reports; case-report · DOI 10.3389/fmed.2023.1130012Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
Jones RDO, Petersson K, Tabatabai A, Bao L, Tomkinson H, Schuller AG.
Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-22-0193[Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib].
Zhang L, Wang YS, Lin LZ, Yu YF, Lu S.
Zhonghua Zhong Liu Za Zhi · consensus statement; journal article; english abstract · DOI 10.3760/cma.j.cn112152-20221226-00853Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
Miao K, Zhang X, Wang H, Si X, Zhang L.
Thorac Cancer · research-article; journal article · DOI 10.1111/1759-7714.14848Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Suárez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C, Srinivasan G, Mendez-Vidal MJ, Hartmaier R, Markovets A, Prendergast A, Szabados B, Mousa K, Powles T.
J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1200/jco.22.01414A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers.
Miah K, Vishwanathan K, Scarfe G, Li Y, Hara I, Cantarini M, Argue J, Menakuru SR.
Clin Pharmacol Drug Dev · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/cpdd.1224A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L, Zhao Y, Wen F, Zhang D, Cai J, Chen Z.
Anticancer Drugs · journal article; case reports · DOI 10.1097/cad.0000000000001495Savolitinib for non-small cell lung cancer.
Zaborowska-Szmi M, Szmit S, Krzakowski M, Kowalski DM.
Drugs Today (Barc) · journal article · DOI 10.1358/dot.2023.59.1.3425324Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.
Zhu X, Lu Y, Lu S.
Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers14246122Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring <i>MET</i> exon 14 skipping alterations: a <i>post hoc</i> analysis of a pivotal phase 2 study.
Yu Y, Ren Y, Fang J, Cao L, Liang Z, Guo Q, Han S, Ji Z, Wang Y, Sun Y, Chen Y, Li X, Xu H, Zhou J, Jiang L, Cheng Y, Han Z, Shi J, Chen G, Ma R, Fan Y, Sun S, Jiao L, Jia X, Wang L, Lu P, Xu Q, Luo X, Su W, Lu S.
Ther Adv Med Oncol · research-article; journal article · DOI 10.1177/17588359221133546Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
Li A, Chen HJ, Yang JJ.
Clin Lung Cancer · clinical trial protocol; research support, non-u.s. gov't; journal article · DOI 10.1016/j.cllc.2022.09.009Savolitinib: First Approval.
Markham A.
Drugs · review; journal article · DOI 10.1007/s40265-021-01584-0Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.
Lim SM, Yang SD, Lim S, Shim HS, Cho BC.
JTO Clin Res Rep · brief-report; journal article · DOI 10.1016/j.jtocrr.2021.100180A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Sahota T, Dota CD, Vik T, Yan W, Verheijen RB, Walker S, Li Y, Goldwater R, Ghiorghiu D, Mellemgaard A, Ahmed GF.
Clin Pharmacol Drug Dev · comparative study; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpdd.896A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity.
Jones RDO, Grondine M, Borodovsky A, San Martin M, DuPont M, D'Cruz C, Schuller A, Henry R, Barry E, Castriotta L, Anjum R, Petersson K, Sahota T, Ahmed GF.
Br J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1111/bph.15301A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX, Li W, Liu XQ, Yang N, Zhou C, Huang JA, Frigault MM, Hartmaier R, Ahmed GF, Egile C, Morgan S, Verheijen RB, Mellemgaard A, Yang L, Wu YL.
Invest New Drugs · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-020-01010-4Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L'Hernault A, Szijgyarto Z, Signoretti S, Albiges L.
JAMA Oncol · clinical trial, phase iii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jamaoncol.2020.2218